Bitte beachten Sie, dass die von Ihnen aufgerufene Seite nicht in Ihrer Standardsprache vorliegt. Sie nutzen unsere Plattform nun in einer anderen Sprache.
This statistic shows the total liabilities of the French pharmaceutical group Ipsen from 2014 to 2019 in million euros. The total liabilities of the group accounted for approximately 4.3 billion euros in 2019. This figure increased compared to 2014 and 2015, when total liabilities of the group reached 1.7 and 1.9 billion euros respectively. On another note, Ipsen total equity was worth 1.75 billion euros in 2019.
Total liabilities of the French pharmaceutical group Ipsen from 2014 to 2019 (in million euros)
Basic Account
Get to know the platform
You only have access to basic statistics.
This statistic is not included in your account.
Starter Account
The ideal entry-level account for individual users
- Instant access to 1m statistics
- Download in XLS, PDF & PNG format
- Detailed references
$199 USD / Month *
Professional Account
Full access
Business Solutions including all features.
* Prices do not include sales tax.
Other statistics that may interest you Statistics on
About the industry
10
- Premium Statistic Total equity of the Ipsen group 2014-2019
- Premium Statistic Research and development expenditure of the Ipsen group 2014-2019
- Premium Statistic Operating profit of the Ipsen group 2014-2019
- Premium Statistic Consolidated net profit of the Ipsen group 2014-2019
- Premium Statistic Total assets of the Ipsen group 2014-2019
- Basic Statistic Orphan drug sales worldwide by therapy category 2028
- Basic Statistic Orphan vs. non-orphan pipeline sales forecast worldwide 2023-2028
- Basic Statistic Top drugs based on projected 2024 global sales
- Premium Statistic Commercial expenses of the Ipsen group 2014-2019
- Premium Statistic Global revenue in general medicine of the Ipsen group 2014-2019
About the region
10
- Premium Statistic Orphan vs. non-orphan drugs median cost per patient per year 2014-2018
- Premium Statistic Market cap of select pharma companies with strong pipeline 2017
- Basic Statistic Members of EFPIA's pharmaceutical exports and imports 1990-2022
- Premium Statistic Top global companies by orphan drug revenues 2023
- Basic Statistic Worldwide Rx drug sales excluding generics and orphan drugs 2012-2026
- Premium Statistic Global revenue in specialty medicine of the Ipsen group 2014-2019
- Premium Statistic Global revenue of the Ipsen group 2019, by geographical area
- Premium Statistic Members of EFPIA's pharmaceutical market value 2000-2022
- Basic Statistic Allocation of R&D investments in pharmaceutical industry by function 2021
- Premium Statistic Merck & Co.'s top-selling drugs 2023
Selected statistics
5
- Premium Statistic Expenditure worldwide on diabetes by market 2013-2018
- Premium Statistic Medicinal market growth worldwide including rebates 2009-2018
- Basic Statistic AstraZeneca's revenue from top product Pulmicort 2006-2023
- Premium Statistic Chinese insulin market distribution: leading companies 2011
- Premium Statistic U.S. insulin market distribution: leading companies 2011
Other regions
10
- Premium Statistic Revenue from pharmaceutical manufacturer in Denmark 2009-2023
- Basic Statistic Top U.S. oncology products by revenue in 2016
- Premium Statistic Members of EFPIA's pharmaceutical R&D spending 1990-2022
- Basic Statistic Leading pharmaceutical companies in Norway 2021, by revenue
- Premium Statistic Market share of Celltrion's Remsima in Europe Q1 2015-Q2 2018
- Premium Statistic Italy: number of R&D employees of biotech pharma companies 2014-2017
- Premium Statistic Mexico: pharmaceutical production 2017-2022
- Premium Statistic Global revenue of the Ipsen group 2014-2019
- Premium Statistic Biopharmaceutical market size forecast Japan 2011-2020
- Premium Statistic Foreign-to-Canadian generic drug price ratios by OECD country as of 2018
Related statistics
10
- Basic Statistic Ipsen group sales 2019, by therapeutic area
- Basic Statistic Medication sales of the Ipsen Group 2019
- Premium Statistic Revenue of the top ten pharmaceutical companies in France 2021
- Premium Statistic Share of generic drugs in the pharmaceutical market in France 2018
- Basic Statistic Total revenue of the French drug market worldwide 2010-2018
- Premium Statistic Chemical peel facial rejuvenation market size worldwide from 2016-2026
- Basic Statistic Average cost of hospital per day by country 2015
- Basic Statistic Number of employees of pharmaceutical companies by region France 2020
- Premium Statistic Number of companies in the pharmaceutical industry in France 1970-2018
- Premium Statistic Botulinum toxin facial rejuvenation market size worldwide from 2016-2026
Further related statistics
10
- Merck & Co total assets 2009-2023
- Merck & Co - expenditure on research and development 2006-2023
- M&A capacities - changes for the global pharma industry 2008-2015
- Celgene's revenue and net income 2006-2018
- Merck & Co cash dividends declared 2006-2023
- Sanofi's total assets 2007-2023
- Pfizer's revenues in the U.S. and abroad 2009-2023
- Pfizer's ad spending 2006-2023
- Sales of Johnson & Johnson 2006-2023 by region
- Revenue of Sinopharm 2011-2022, by category
Further Content: You might find this interesting as well
Statistics
- Merck & Co total assets 2009-2023
- Merck & Co - expenditure on research and development 2006-2023
- M&A capacities - changes for the global pharma industry 2008-2015
- Celgene's revenue and net income 2006-2018
- Merck & Co cash dividends declared 2006-2023
- Sanofi's total assets 2007-2023
- Pfizer's revenues in the U.S. and abroad 2009-2023
- Pfizer's ad spending 2006-2023
- Sales of Johnson & Johnson 2006-2023 by region
- Revenue of Sinopharm 2011-2022, by category
Ipsen. (February 13, 2020). Total liabilities of the French pharmaceutical group Ipsen from 2014 to 2019 (in million euros) [Graph]. In Statista. Retrieved May 19, 2024, from https://www.statista.com/statistics/1073033/ipsen-total-liabilities-french-company/
Ipsen. "Total liabilities of the French pharmaceutical group Ipsen from 2014 to 2019 (in million euros)." Chart. February 13, 2020. Statista. Accessed May 19, 2024. https://www.statista.com/statistics/1073033/ipsen-total-liabilities-french-company/
Ipsen. (2020). Total liabilities of the French pharmaceutical group Ipsen from 2014 to 2019 (in million euros). Statista. Statista Inc.. Accessed: May 19, 2024. https://www.statista.com/statistics/1073033/ipsen-total-liabilities-french-company/
Ipsen. "Total Liabilities of The French Pharmaceutical Group Ipsen from 2014 to 2019 (in Million Euros)." Statista, Statista Inc., 13 Feb 2020, https://www.statista.com/statistics/1073033/ipsen-total-liabilities-french-company/
Ipsen, Total liabilities of the French pharmaceutical group Ipsen from 2014 to 2019 (in million euros) Statista, https://www.statista.com/statistics/1073033/ipsen-total-liabilities-french-company/ (last visited May 19, 2024)
Total liabilities of the French pharmaceutical group Ipsen from 2014 to 2019 (in million euros) [Graph], Ipsen, February 13, 2020. [Online]. Available: https://www.statista.com/statistics/1073033/ipsen-total-liabilities-french-company/